Tiziana Life Sciences Ltd
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $140.0M
- Price
- $1.10
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.90%
- Volume
- 384.6K
About
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
Quick stats
Shares outstanding127.3M
Computed float64.8M
Float / shares50.9%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001723069
AI Summary
AI-generated1/28
minorbullishregulatory
Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)
Tiziana Life Sciences has submitted a request to the FDA for Orphan Drug Designation for intranasal foralumab in Multiple System Atrophy, a rare neurodegenerative disease with no approved disease-modifying therapies.
If granted, the designation would provide seven years of market exclusivity upon approval, tax credits for clinical testing, and fee waivers; the FDA aims to complete its review within 90 days.
Foralumab is currently in a Phase 2a open-label trial in MSA patients at Brigham and Women's Hospital led by Dr. Vikram Khurana, and in Phase 2 trials in non-active secondary progressive multiple sclerosis.
Red flags
- ODD request is only a filing, not a grant; FDA decision pending and not guaranteed